Establishing Non-Inferiority of a New Treatment in a Three-Arm Trial: Apply a Step-Down Hierarchical Model in a Papulopustular Acne Study and an Oral Prophylactic Antibiotics Study
DOI:
https://doi.org/10.6000/1929-6029.2014.03.01.3Keywords:
Clinical trial, binary outcomes, gold standard design, optimal sample size allocation, restricted maximum likelihoodAbstract
Clinical trials comparing a test treatment with an active control therapy have become very popular in drug and medical device development in the last decade. An active controlled trial without a placebo, however, exhibits some major challenges in design, analysis, and interpretation, such as the determination of the non-inferiority margin or the assumption of constancy condition. When there are no ethical concerns, the comparison of a test drug with placebo usually provides the most convincing proof of the efficacy of a new treatment. Therefore, it may be advisable to conduct a three-arm trial — including placebo, active control, and the new treatment — if it is ethically justifiable such as a papulopustular acne study and an oral prophylactic antibiotics study. In this paper, we propose a statistical methodology for a three-arm non-inferiority trial with binary outcomes. We adapt the step-down hierarchical hypotheses and give a three-step testing procedure which is more realistic in conducting a clinical trial. We derived an optimal sample size allocation rule in an ethical and reliable manner to minimize the total sample size and hence to shorten the duration of the trials. Real examples from a papulopustular acne study and an oral prophylactic antibiotics study are used to demonstrate our methodology.
References
International Conference on Harmonisation. Guidance on choice of control group and related design and conduct issues in clinical trials (ICH E10), 2000. Available from URL: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E10/Step4/E10_Guideline.pdf
Committee for Medicinal Products for Human Use (CHMP). Guideline on the choice of the non-inferiority margin. EMEA/CPMP/EWP/2158/99, 2005. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003636.pdf
Pigeot I, Schäfer J, Röhmel J, Hauschke D. Assessing non-inferiority in a new treatment in a three-arm clinical trial including a placebo. Stat Med 2003; 22: 883-99. http://dx.doi.org/10.1002/sim.1450 DOI: https://doi.org/10.1002/sim.1450
Koch A, Röhmel J. Hypothesis testing in the “Gold standard” design for proving the efficacy of an experimental treatment relative to placebo and a reference. J Biopharm Stat 2004; 14: 315-25. http://dx.doi.org/10.1081/BIP-120037182 DOI: https://doi.org/10.1081/BIP-120037182
Hauschke D, Pigeot I. Establishing efficacy of a new experimental treatment in the ‘Gold Standard’ design. Biom J 2005; 47: 782-6. http://dx.doi.org/10.1002/bimj.200510169 DOI: https://doi.org/10.1002/bimj.200510169
Tang ML, Tang NS. Tests of noninferiority via rate difference for three-arm clinical trials with placebo. J Biopharm Stat 2004; 14: 337-47. http://dx.doi.org/10.1081/BIP-120037184 DOI: https://doi.org/10.1081/BIP-120037184
Kieser M, Friede T. Planning and analysis of three-arm non-inferiority trials with binary endpoints. Stat Med 2007; 26: 253-73. http://dx.doi.org/10.1002/sim.2543 DOI: https://doi.org/10.1002/sim.2543
Hasler M. Multiple comparisons to both a negative and a positive control. Pharm Stat 2012; 11: 74-81. http://dx.doi.org/10.1002/pst.503 DOI: https://doi.org/10.1002/pst.503
Mielke M, Munk A, Schacht A. Assessment of non-inferiority in a gold standard design with censored, exponentially distributed endpoints. Stat Med 2008; 27: 5093-110. http://dx.doi.org/10.1002/sim.3348 DOI: https://doi.org/10.1002/sim.3348
Kombrink K, Munk A, Friede T. Design and semiparametric analysis of non-inferiority trials with active and placebo control for censored time-to-event data. Stat Med 2013; 32: 3055-66. http://dx.doi.org/10.1002/sim.5769 DOI: https://doi.org/10.1002/sim.5769
Koch GG, Tangen CM. Nonparametric analysis of covariance and its role in noninferiority clinical trials. Drug Inf J 1999; 33: 1145-59. http://dij.sagepub.com/content/33/4/1145.short DOI: https://doi.org/10.1177/009286159903300419
Chow SC, Shao J, Wang H. Sample size calculations in clinical research. 2nd ed. Boca Raton: Taylor & Francis 2008. DOI: https://doi.org/10.1201/9781584889830
Bickel PJ, Doksum KA. Mathematical statistics: basic ideas and selected topics, 2nd ed. Upper Saddle River, New Jersey: Prentice Hall 2001.
Dunnett CW, Gent M. Significance testing to establish equivalence between treatments with special reference to data in the form of 2 2 tables. Biometrics 1977; 33: 593-602. http://dx.doi.org/10.2307/2529457 DOI: https://doi.org/10.2307/2529457
Farrington CP, Manning G. Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk. Stat Med 1990; 9: 1447-54. http://dx.doi.org/10.1002/sim.4780091208 DOI: https://doi.org/10.1002/sim.4780091208
Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med 1985; 4: 213-26. http://dx.doi.org/10.1002/sim.4780040211 DOI: https://doi.org/10.1002/sim.4780040211
Ernesta PK, Schellschmidt I, Schumacher U, Gräser T. Efficacy of a combined oral contraceptive containing 0.030 mg ethinylestradiol/2 mg dienogest for the treatment of papulopustular acne in comparison with placebo and 0.035 mg ethinylestradiol/2 mg cyproterone acetate. Contraception 2009; 79: 282-9. http://dx.doi.org/10.1016/j.contraception.2008.10.010 DOI: https://doi.org/10.1016/j.contraception.2008.10.010
Johnson MI, Merrilees D, Robson WA, et al. Oral ciprofloxacin or trimethoprim reduces bacteriuria after flexible cystoscopy. BJU Int 2007; 100: 826-9. http://dx.doi.org/10.1111/j.1464-410X.2007.07093.x DOI: https://doi.org/10.1111/j.1464-410X.2007.07093.x
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2014 Jung-Tzu Liu, Chyng-Shyan Tzeng, Hsiao-Hui Tsou
![Creative Commons License](http://i.creativecommons.org/l/by/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Policy for Journals/Articles with Open Access
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are permitted and encouraged to post links to their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work
Policy for Journals / Manuscript with Paid Access
Authors who publish with this journal agree to the following terms:
- Publisher retain copyright .
- Authors are permitted and encouraged to post links to their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work .